AVANIR Pharmaceuticals to Present at the BIO Emerging Company Investor Forum

SAN DIEGO--(BUSINESS WIRE)--Oct. 12, 2004--AVANIR Pharmaceuticals, (AMEX:AVN) will be presenting at the BIO Emerging Company Investor Forum taking place October 13-15, 2004 in San Francisco, California. Dr. Gerald J. Yakatan, President and Chief Executive Officer, will be providing a corporate overview and a review of the Company's lead product, Neurodex(TM), for the treatment of central nervous system disorders.



Event: BIO Emerging Company Investor Forum

Presenter: Gerald J. Yakatan, Ph.D., Chief Executive Officer,
           AVANIR Pharmaceuticals

Date: Wednesday, October 13, 2004

Time: 10:50 am Pacific Time

Location: The Palace Hotel, San Francisco

AVANIR Pharmaceuticals is a drug discovery and development company focused on novel treatments for chronic diseases. The Company's most advanced product candidate, Neurodex(TM), is in Phase III clinical development for pseudobulbar affect, and in Phase II clinical development for neuropathic pain. A potential treatment for allergy and asthma, AVP 13358, is in Phase I clinical development. Preclinical programs include small molecule research in atherosclerosis and inflammation. AVANIR also develops human monoclonal antibodies for infectious diseases and other therapeutic applications. The Company's first commercialized product, Abreva(R), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.

The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in conjunction with the company's most recent Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect". The Company disclaims any intent or obligation to update these forward-looking statements. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.


    CONTACT: AVANIR Pharmaceuticals
             Patrice Saxon, Investor Relations
             858-622-5202
             psaxon@avanir.com

    SOURCE: AVANIR Pharmaceuticals